AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by stock analysts at Shore Capital in a research report issued to clients and investors on Thursday.
Several other research analysts also recently commented on AZN. Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a report on Tuesday, October 23rd. Credit Suisse Group set a GBX 6,350 ($82.97) price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Friday, December 7th. Bryan, Garnier & Co downgraded shares of AstraZeneca to a “neutral” rating in a report on Thursday, November 8th. Barclays reissued an “overweight” rating and set a GBX 6,800 ($88.85) price objective on shares of AstraZeneca in a report on Monday, November 19th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Monday, November 19th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. AstraZeneca has a consensus rating of “Buy” and a consensus target price of GBX 6,243.45 ($81.58).
AZN opened at GBX 6,012 ($78.56) on Thursday. AstraZeneca has a 52 week low of GBX 4,260 ($55.66) and a 52 week high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What are Closed-End Mutual Funds?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.